Identification of BAY61 ‐3606 Derivatives With Improved Activity in Splicing Modulation That Induces Inclusion of Cassette Exons Similar to the Splicing Factor 3B Subunit 1 Mutation
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.70002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Takanori Matsumaru und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Exons, RNA Splicing Factors, RNA Splicing, Mutation. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science London.
Abstract (Originalsprache)
Splicing modulation by a small compound offers therapeutic potential for diseases caused by splicing abnormality. However, only a few classes of compounds that can modulate splicing have been identified. We previously identified BAY61‐3606, a multiple kinase inhibitor, as a compound that relaxes the splicing fidelity at the 3′ splice site recognition. We have also reported the synthesis of derivatives of BAY61‐3606. In this study, we tested those compounds for their splicing modulation capabilities and identified two contrasting compounds. These compounds were further investigated for their effects on the whole transcriptome, and analysis of changes in transcription and splicing revealed that the highly active derivative in the splicing reporter assay also showed significantly higher activity in modulating the splicing of endogenously expressed genes. Particularly, cassette exon inclusion was highly upregulated by this compound, and clustering analysis revealed that these effects resembled those in splicing factor 3b subunit 1 (SF3B1) K700E mutant cells but contrasted with those of the splicing inhibitor H3B‐8800. Additionally, a group of serine/arginine‐rich (SR) protein genes was identified as representatively affected, likely via modulation of poison exon inclusion. This finding could guide further analysis of the mode of action of these compounds on splicing, which could be valuable for developing drugs for diseases associated with splicing abnormalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
- School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
- Graduate School of Life Science, Hokkaido University, Sapporo, Japan.
- Comparative Genomics Laboratory, National Institute of Genetics, Mishima, Shizuoka, Japan.
ORCID-Profile: Hiroshi Maita
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science London
Zitieren
APA
Matsumaru, T., Iwamatsu, T., Ishigami, K., Inai, M., Kanto, W., Ishigaki, A., Toyoda, A., Shuto, S., Maenaka, K., Nakagawa, S., & Maita, H. (2024). Identification of BAY61 ‐3606 Derivatives With Improved Activity in Splicing Modulation That Induces Inclusion of Cassette Exons Similar to the Splicing Factor 3B Subunit 1 Mutation. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70002
Vancouver
Matsumaru T, Iwamatsu T, Ishigami K, Inai M, Kanto W, Ishigaki A, et al. Identification of BAY61 ‐3606 Derivatives With Improved Activity in Splicing Modulation That Induces Inclusion of Cassette Exons Similar to the Splicing Factor 3B Subunit 1 Mutation. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.70002
BibTeX
@article{Matsumaru2024,
author = {Matsumaru, Takanori and Iwamatsu, Toshiki and Ishigami, Kana and Inai, Makoto and Kanto, Wataru and Ishigaki, Ayumi and Toyoda, Atsushi and Shuto, Satoshi and Maenaka, Katsumi and Nakagawa, Shinichi and Maita, Hiroshi},
title = {Identification of BAY61 ‐3606 Derivatives With Improved Activity in Splicing Modulation That Induces Inclusion of Cassette Exons Similar to the Splicing Factor 3B Subunit 1 Mutation},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.70002}
}
EUVIMED